Latest news with #KrsnaaDiagnostics
Business Standard
5 days ago
- Business
- Business Standard
Krsnaa Diagnostics consolidated net profit rises 14.51% in the June 2025 quarter
Sales rise 13.36% to Rs 192.98 crore Net profit of Krsnaa Diagnostics rose 14.51% to Rs 20.52 crore in the quarter ended June 2025 as against Rs 17.92 crore during the previous quarter ended June 2024. Sales rose 13.36% to Rs 192.98 crore in the quarter ended June 2025 as against Rs 170.23 crore during the previous quarter ended June 2024. Particulars Quarter Ended Jun. 2025 Jun. 2024 % Var. Sales 192.98170.23 13 OPM % 26.6325.06 - PBDT 49.0544.67 10 PBT 27.4223.20 18 NP 20.5217.92 15
&w=3840&q=100)
Business Standard
08-07-2025
- Business
- Business Standard
Krsnaa Diagnostics rises 6% in trade; what's driving investor interest?
Krsnaa Diagnostics shares gained 6 per cent in trade on Tuesday, logging an intraday high at ₹789.1 per share. At 10:40 AM, Krsnaa Diagnostics shares were trading 3.11 per cent higher at ₹763 per share on the BSE. In comparison, the BSE Sensex was up 0.01 per cent at 83,447.28. The company's market capitalisation stood at ₹ 1,041.8 crore. Its 52-week high was at ₹628 per share. Why were Krsnaa Diagnostics shares in demand? The northward movement in the stock came after the High Court of Rajasthan passed an order in the favour of Krsnaa Diagnostics and its consortium partner, Telecommunications Consultants India. The order was regarding the Letter of Acceptance (LoA) issued by the National Health Mission, Rajasthan for providing laboratory services under the Free Diagnostics Initiative on HUB and SPOKE Model under NHM across the state of Rajasthan. Further, according to the company's exchange filing, the Government of Rajasthan has issued a new LoA which has been received by the company and the consortium. In July 2023, the National Health Mission, Rajasthan cancelled the LoA for providing laboratory services in the state under a free diagnostics initiative on the hub and spoke model. Citing the reason the company said that as part of the tender requirements, there were requirements of provision of submitting additional performance security. There were disagreements over providing this additional performance security due to certain technicalities. "Whilst we have made various representations to the authorities on the same as well as communicated our willingness and commitment to execute the agreement. However, to our disappointment, the authorities decided to cancel the letter of acceptance," the filing said. The company, further, said in collaboration with Telecommunications Consultants India, it has taken legal recourse and legal counsels are actively pursuing this matter with utmost dedication and diligence. In May 2023, the company accepted the LoA issued as lead bidder. Krsnaa Diagnostics is India's fastest growing differentiated diagnostic services provider both in Radiology and Pathology.
Time of India
24-06-2025
- Health
- Time of India
BMC's subsidised diagnostic testing programme Aapli Chikitsa set to restart soon in Mumbai
Mumbai: While the incidence of monsoon diseases is rising in the city, the BMC's subsidised diagnostic testing programme will take a few more weeks to become operational again. "Our Aapli Chikitsa programme is on the verge of being finalised. We need a week or so to get it operational," confirmed deputy municipal commissioner Sharad Ughade. The scheme lapsed in Dec 2024 after the BMC failed to appoint a new agency to carry out diagnostic tests after the old contract expired. In April, a Pune-based company, Lifenity Health Ltd, emerged as the lowest bidder in the BMC's tender process, offering a rate of Rs 90 against the estimated cost of Rs 100 for basic tests. The final decision will be made within a week, Ughade said. The BMC subsidised tests — nearly 100 basic and 40 advanced tests — by paying the difference to the empaneled company. The previously empaneled company, Krsnaa Diagnostics, offered a rate of Rs 86 for basic tests. You Can Also Check: Mumbai AQI | Weather in Mumbai | Bank Holidays in Mumbai | Public Holidays in Mumbai A senior BMC official said the scheme should be back within a month. BMC executive health officer Dr Daksha Shah said tests are still being conducted at free or subsidised rates for patients visiting BMC healthcare centres and hospitals. Regarding reports of a few suburban hospitals lacking the quick-test Elisa kits used for the detection of various diseases, including dengue, an official said: "Even if there is a shortage of Elisa kits, hospitals can collect blood samples and send them for testing at our lab in Kasturba Hospital. "
Business Standard
13-05-2025
- Business
- Business Standard
Krsnaa Diagnostics consolidated net profit rises 10.41% in the March 2025 quarter
Sales rise 11.91% to Rs 186.08 crore Net profit of Krsnaa Diagnostics rose 10.41% to Rs 20.68 crore in the quarter ended March 2025 as against Rs 18.73 crore during the previous quarter ended March 2024. Sales rose 11.91% to Rs 186.08 crore in the quarter ended March 2025 as against Rs 166.28 crore during the previous quarter ended March 2024. For the full year,net profit rose 36.54% to Rs 77.61 crore in the year ended March 2025 as against Rs 56.84 crore during the previous year ended March 2024. Sales rose 15.74% to Rs 717.16 crore in the year ended March 2025 as against Rs 619.63 crore during the previous year ended March 2024. Particulars Quarter Ended Year Ended Mar. 2025 Mar. 2024 % Var. Mar. 2025 Mar. 2024 % Var. Sales 186.08166.28 12 717.16619.63 16 OPM % 28.4726.28 - 26.5123.28 - PBDT 50.5640.72 24 191.01144.55 32 PBT 28.6122.61 27 102.6970.01 47 NP 20.6818.73 10 77.6156.84 37
Time of India
24-04-2025
- Health
- Time of India
BMC's subsidised diagnostic tests scheme all set to restart
Mumbai: After a gap of four months, the civic administration could soon restart its ambitious Aapli Chikitsa programme to provide diagnostic tests for free or at subsidised rates to citizens. Lifenity Health Ltd , headquartered in Pune and with a laboratory in Lower Parel, has emerged as the lowest bidder in the BMC's tender process, offering a rate of Rs 90 against the estimated cost of Rs 100 for basic tests. The BMC subsidises these tests—nearly 100 basic tests and 40 advanced tests—by paying the difference to the empanelled company. The previously empanelled company, Krsnaa Diagnostics, had a rate of Rs 86 for basic tests. However, their nearly two-year tenure was marred by delays in handing over patients' diagnostic reports, disrupted service in many hospitals, as well as protests over BMC's alleged delays in clearing dues. This time around, a senior BMC official said, the rates were better discussed. "Against an estimated cost of Rs 376, we got a bid for Rs 495 for the advanced tests," he said. The official mentioned that the appointment of a contractor would be finalised soon as there is an "urgent requirement" to get the diagnostic process operational again in the city ahead of the monsoons. Over 4,000 blood samples would be collected every day on average by the Aapli Chikitsa contractor from the Brihanmumbai Municipal Corporation's public healthcare machinery—ranging from dispensaries, HBT or mohalla clinics, to suburban hospitals. Infectious diseases such as malaria, leptospirosis, gastroenteritis, hepatitis, and dengue are among the most commonly conducted tests in monsoons. This time around, the BMC received two bids for the tender—one from Lifinity and another from Thyrocare Lab. Samajwadi Party MLA and former BMC corporator Rais Shaikh said that the Aapli Chikitsa scheme is much needed and the municipal corporation should have ensured that a new contractor was appointed long before the earlier contract expired. "When the authorities knew that the contract was ending, they should have ensured that there is a new contractor in place. This gap with free diagnostic service only impacts citizens," Shaikh said. However, officials of the BMC denied that patients were affected by the delay in restarting the subsidised tests scheme. The old contract ended on December 15, 2024, but the BMC rolled out a standard operating procedure to get the tests done in-house. "The BMC invited bids and received bids from two diagnostic companies but could not finalise a company and award the contract as the companies failed to negotiate a lower price with the BMC," said an official. In the previous tender, Krsnaa Diagnostics was awarded the contract by the BMC for four years. But the total quantity of tests was fixed, and this amount got exhausted, effectively ending the contract. A public health expert said that the rates mentioned in the BMC's tender documents are not feasible to conduct basic tests. "Even if the costs of testing are low, how does one account for salaries of phlebotomists and paramedical workers at such low rates? Delays and protests are likely to continue," said the doctor, who didn't want to be identified.
